You might also like
McKesson Corporation is a leading healthcare services and information technology company that operates through four main segments, focusing on the distribution of pharmaceutical and medical products, which account for the majority of its revenues . The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and healthcare-related products in the United States, and provides practice management, technology, clinical support, and business solutions to specialty practices . McKesson also addresses medication access and affordability challenges, offers medical-surgical supply distribution, and operates internationally in Canada and Europe .
- U.S. Pharmaceutical - Distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products in the United States, and provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices .
- Prescription Technology Solutions (RxTS) - Addresses medication access, affordability, and adherence challenges by connecting patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies, offering prescription price transparency, benefit insight, dispensing support services, and third-party logistics .
- Medical-Surgical Solutions - Provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies, offering national brand medical-surgical products and McKesson's own line of products .
- International - Includes operations in Canada and Europe, providing non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services, with Canadian operations delivering medicines, supplies, and information technology solutions, and European operations focusing on distribution and services in Norway .
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Brian S. Tyler Executive | Chief Executive Officer | Board Member at Republic Services, Inc., IFPW, IFPW Foundation, CEOs Against Cancer | CEO since April 2019, over 25 years at McKesson, extensive leadership roles, Ph.D. in Economics. | View Report → |
Britt J. Vitalone Executive | Executive Vice President and Chief Financial Officer | None | CFO since January 2018, previously held various financial leadership roles at McKesson. | |
LeAnn B. Smith Executive | Executive Vice President and Chief Human Resources Officer | None | Joined McKesson in 2021, previously at Walmart, appointed EVP and CHRO in December 2022. | |
Michele Lau Executive | Executive Vice President and Chief Legal Officer | None | Rejoined McKesson as EVP and Chief Legal Officer on January 1, 2024, extensive legal experience. | |
Thomas L. Rodgers Executive | Executive Vice President, Chief Strategy and Business Development Officer | None | EVP since June 2020, previously Senior VP and Managing Director of McKesson Ventures. | |
Dominic J. Caruso Board | Director | Board member at Kyndryl Holdings, Inc., Trustee of Cystic Fibrosis Foundation | Director since September 2018, retired CFO of Johnson & Johnson, extensive financial expertise. | |
Donald R. Knauss Board | Director | Board member at University of San Diego, Kellanova, Target Corporation | Director since 2014, retired from The Clorox Company, extensive leadership experience. | |
James H. Hinton Board | Director | Operating Partner at Welsh, Carson, Anderson & Stowe | Director since 2022, extensive healthcare operations experience. | |
Kathleen Wilson-Thompson Board | Director | Board member at Tesla, Inc., Wolverine World Wide, Inc., Chair of University of Michigan Alumni Association, NAACP Foundation | Director since 2022, retired EVP and CHRO of Walgreens Boots Alliance, extensive HR experience. | |
Kevin Ozan Board | Director | Board member at Cineworld, The Hershey Company | Director since January 2024, retired from McDonald's Corporation, extensive financial leadership experience. | |
Linda P. Mantia Board | Director | Board member at Ceridian HCM Holding Inc., Maple Leaf Foods Inc., Sunnybrook Health Sciences Centre | Director since 2020, significant experience in financial services and corporate strategy. | |
Maria Martinez Board | Director | Board member at Cue Health Inc. | Director since 2019, former EVP and COO at Cisco Systems, recognized for leadership in technology. | |
Richard H. Carmona Board | Director | Chief of Health Innovations at Canyon Ranch, Inc., Board member at Herbalife Nutrition Ltd., Better Therapeutics, Inc. | Director since 2021, former U.S. Surgeon General, extensive public health and academic experience. | |
Susan R. Salka Board | Director | Member of Women Business Leaders, Women Corporate Directors Foundation, Editorial Advisory Board of Directors & Boards Magazine | Director since 2014, significant leadership experience in healthcare services. | |
W. Roy Dunbar Board | Director | Board member at Duke Energy Corp., Johnson Controls International plc, SiteOne Landscape Supply, Inc. | Director since 2022, former CEO of Network Solutions, extensive technology and operations experience. |
- With the acquisition of Rx Savings Solutions aiming to provide price transparency to employers and employees, how does McKesson plan to leverage this capability to impact drug pricing or influence drug utilization patterns, and what is the long-term strategic vision for integrating this asset into your overall strategy?
- Given the evolving landscape of U.S. retail pharmacies and the closures of many stores, would McKesson consider changing its domestic strategy by owning a virtual pharmacy to capitalize on emerging opportunities, despite previous beliefs about customer conflict and operational challenges?
- As oncology care shifts towards value-based models, how is McKesson adapting its services to support providers in this transition, and what specific initiatives or partnerships are you pursuing to facilitate success in value-based oncology care?
- In light of competitive pressures from companies serving both acute care facilities and alternate sites, especially with large integrated delivery networks (IDNs) owning both assets, how does McKesson plan to address potential market changes and growth opportunities, and is there a need to rethink your approach to the medical distribution market?
- Considering your expansion into specialties like retina and ophthalmology through acquisitions, does McKesson have plans to build comprehensive platforms in other specialty areas similar to your oncology platform, and how do you evaluate the potential for achieving similar success outside of oncology?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Considered one of the largest competitors in distribution, wholesaling, and logistics in the pharmaceutical distribution environment in which the U.S. Pharmaceutical and International segments operate. | |
Considered one of the largest competitors in distribution, wholesaling, and logistics in the pharmaceutical distribution environment in which the U.S. Pharmaceutical and International segments operate. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
CVS Health Corporation | Pharmaceutical distribution partner; extended to June 2027. | All | Revenue: 28% of total consolidated revenues ($308,951 million ) = $86,506 million. <br>Accounts Receivable: 24% of net trade accounts receivable ($21,622 million ) = $5,189 million. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
PRISM Vision Holdings | 2025 | McKesson will acquire an 80% controlling interest in PRISM Vision Holdings for approximately $850 million (cash and debt), with physicians retaining 20%. The acquisition is strategically aimed at expanding McKesson’s retina and ophthalmology services and is expected to be accretive to earnings post-closing. |
Community Oncology Revitalization Enterprise Ventures (Core Ventures) | 2024 | McKesson signed an agreement to acquire a 70% controlling interest in Core Ventures for approximately $2.49 billion in cash, to enhance its oncology platform and integrate the business into its U.S. Pharmaceutical segment, pending regulatory approvals including an FTC review. |
Compile, Inc. | 2024 | Acquired on January 4, 2024, Compile, Inc. is a healthcare data platform that strengthens McKesson’s data capabilities and supports its growth in oncology and biopharma by providing integrated, centralized commercial insights. |
Rx Savings Solutions, LLC | 2022 | Completed on November 1, 2022, the acquisition of Rx Savings Solutions involved an upfront payment of approximately $600 million plus up to $275 million contingent on performance, expanding McKesson's biopharma and payer services within its Prescription Technology Solutions segment. |
Genospace | 2022 | Completed on October 31, 2022, the acquisition of Genospace enhances McKesson’s oncology data and analytics capabilities—especially in precision medicine and clinical trial matching—through a joint venture (with McKesson holding a 51% controlling interest) integrated into the U.S. Pharmaceutical segment. |
No recent press releases or 8-K filings found for MCK.